⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of ALX Oncology and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
ALX Oncology
↗South San Francisco, United States
ALX Oncology is a publicly traded, clinical-stage biotechnology company focused on developing oncology therapies that activate innate and adaptive immune responses. Its lead candidate, evorpacept, is a next-generation CD47-blocking fusion protein designed to inhibit the tumor-cell "don't eat me" signal while using an inactivated Fc domain intended to reduce hematologic toxicity and support combination treatment with other anticancer agents. ([alxoncology.com](https://alxoncology.com/?utm_source=openai))
The company’s second clinical-stage program is ALX2004, an EGFR-targeted antibody-drug conjugate incorporating a matuzumab-derived antibody, a proprietary topoisomerase-I-inhibitor payload, and a cleavable linker. ALX2004 entered a first-in-human Phase 1 study in 2025. ALX Oncology has no approved commercial products and remains dependent on clinical development, capital markets, partnerships, and external manufacturing providers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1810182/000119312526098454/alxo-20251231.htm?utm_source=openai))
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$0-$10M; the company states it has no product revenue and no approved products. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1810182/000119312526098454/alxo-20251231.htm?utm_source=openai))
Founded:2015
Ownership:public
Status:operating
FUNDING
Stage:Public / post-IPO clinical-stage
Total Raised:At least $783.9M net disclosed through 2026-02, calculated from $643.5M raised through 2025-06 plus $140.4M net proceeds from the February 2026 offering; gross financing totals are higher. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1810182/000095017025107303/alxo-20250630.htm?utm_source=openai))
Investors:Vivo Capital, Logos Capital, Janus Henderson Investors, Foresite Capital, Cormorant Asset Management, BVF Partners / Biotechnology Value Fund, HBM Healthcare Investments, venBio Partners, Lightstone Ventures, Oxford Finance, Silicon Valley Bank, Ireland Strategic Investment Fund
STOCK
Exchange:Nasdaq Global Select Market
Ticker:ALXO
Market Cap:$282.1M as of 2026-08-19
PIPELINE
Stage:Phase 1 / Phase 2
Lead Drug Stage:Phase 2
Modalities:SIRPα-CD47 fusion protein, Immune checkpoint blockade, Biologic combination therapy, Antibody-drug conjugate, Monoclonal-antibody-derived targeting domains, Topoisomerase-I inhibitor payloads
Active Trials:3
Trial Phases:Phase 1: 2 | Phase 2: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:ALX Oncology Limited, an Irish wholly owned subsidiary, ALX Oncology Inc., a Delaware wholly owned subsidiary
Key Partnerships:Sanofi — sponsors and manages the SARCLISA/isatuximab plus dexamethasone and evorpacept Phase 1/2 multiple-myeloma study; ALX Oncology supplies evorpacept. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1810182/000119312526098454/alxo-20251231.htm?utm_source=openai)), Jazz Pharmaceuticals — collaboration on the zanidatamab plus evorpacept Phase 1b/2 study in HER2-expressing cancers. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05027139?utm_source=openai)), Eli Lilly — supplies CYRAMZA/ramucirumab for the ASPEN-06 program. ([alxoncology.com](https://alxoncology.com/pipeline/?utm_source=openai)), Merck & Co. — pembrolizumab collaboration in the ASPEN-03 and ASPEN-04 head-and-neck cancer programs. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04675294?utm_source=openai)), Stanford University — worldwide royalty-bearing license relating to high-affinity SIRPα variant polypeptides used in the evorpacept platform. ([ir.alxoncology.com](https://ir.alxoncology.com/static-files/ba7ccda6-ec00-4fef-b5f4-a80a7c2051bc?utm_source=openai))
COMPETITION
Position:Emerging
Competitors:Gilead Sciences / Forty Seven, Pfizer / Trillium Therapeutics, Akeso, I-Mab, Pyxis Oncology / Apexigen, Zai Lab, Boehringer Ingelheim, Bio-Thera Solutions +13 more
LEADERSHIP
Key Executives:
Jason Lettmann - Chief Executive Officer
Barbara Klencke, M.D. - Chief Medical Officer
Jeff Knight, M.P.H. - Chief Development & Operating Officer
Michael Listgarten - General Counsel
Harish Shantharam, CFA - Chief Financial Officer
Shelly Wong, CPA - Senior Vice President, Finance and Chief Accounting Officer
Scientific Founders:Corey Goodman, Ph.D. — co-founder; neuroscientist, former Pfizer Biotherapeutics and Bioinnovation Center president, and founder of Labrys and Renovis. ([ir.alxoncology.com](https://ir.alxoncology.com/board-member/corey-goodman/?utm_source=openai)), K. Christopher Garcia, Ph.D. — co-founder and Stanford structural-immunology scientist. ([annualreports.com](https://www.annualreports.com/HostedData/AnnualReportArchive/a/NASDAQ_ALXO_2021.pdf?utm_source=openai)), Jaume Pons, Ph.D. — co-founder and former CEO from inception through September 2023. ([venbio.com](https://www.venbio.com/team/jaume-pons-phd/?utm_source=openai))
Board Members:Scott Garland — Chairman. ([alxoncology.com](https://alxoncology.com/about-us/board-of-directors/)), Daniel J. Curran, M.D. — Director. ([alxoncology.com](https://alxoncology.com/about-us/board-of-directors/)), Rekha Hemrajani — Director. ([alxoncology.com](https://alxoncology.com/about-us/board-of-directors/)), Jason Lettmann — Director and Chief Executive Officer. ([alxoncology.com](https://alxoncology.com/about-us/board-of-directors/)), Alan Sandler, M.D. — Director; formerly ALX Oncology Chief Medical Officer. ([alxoncology.com](https://alxoncology.com/about-us/board-of-directors/)), Chris H. Takimoto, M.D., Ph.D., FACP — Director. ([alxoncology.com](https://alxoncology.com/about-us/board-of-directors/))
LINKS
Website:alxncology.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with ALX Oncology. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.